Synonym
NXPZ-2; NXPZ2; NXPZ 2;
IUPAC/Chemical Name
2-((N-(4-((4-amino-N-(2-amino-2-oxoethyl)phenyl)sulfonamido)naphthalen-1-yl)-4-methoxyphenyl)sulfonamido)acetamide
InChi Key
DFIZGWXPFCOCFG-UHFFFAOYSA-N
InChi Code
InChI=1S/C27H27N5O7S2/c1-39-19-8-12-21(13-9-19)41(37,38)32(17-27(30)34)25-15-14-24(22-4-2-3-5-23(22)25)31(16-26(29)33)40(35,36)20-10-6-18(28)7-11-20/h2-15H,16-17,28H2,1H3,(H2,29,33)(H2,30,34)
SMILES Code
NC(CN(S(C1=CC=C(N)C=C1)(=O)=O)C2=CC=C(N(S(C3=CC=C(OC)C=C3)(=O)=O)CC(N)=O)C4=CC=CC=C42)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
597.66
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Sun Y, Xu L, Zheng D, Wang J, Liu G, Mo Z, Liu C, Zhang W, Yu J, Xing C, He L, Zhuang C. A potent phosphodiester Keap1-Nrf2 protein-protein interaction inhibitor as the efficient treatment of Alzheimer's disease. Redox Biol. 2023 Aug;64:102793. doi: 10.1016/j.redox.2023.102793. Epub 2023 Jun 24. PMID: 37385075; PMCID: PMC10331597.
2: Yan J, Li Y, Ding L, Hou R, Xing C, Jiang C, Miao Z, Zhuang C. Fragment-Based Discovery of Azocyclic Alkyl Naphthalenesulfonamides as Keap1-Nrf2 Inhibitors for Acute Lung Injury Treatment. J Med Chem. 2023 Jun 22;66(12):8267-8280. doi: 10.1021/acs.jmedchem.3c00686. Epub 2023 May 31. PMID: 37257073.
3: Liu G, Hou R, Xu L, Zhang X, Yan J, Xing C, Xu K, Zhuang C. Crystallography- Guided Optimizations of the Keap1-Nrf2 Inhibitors on the Solvent Exposed Region: From Symmetric to Asymmetric Naphthalenesulfonamides. J Med Chem. 2022 Jun 23;65(12):8289-8302. doi: 10.1021/acs.jmedchem.2c00170. Epub 2022 Jun 10. PMID: 35687391.
4: Zhang L, Xu L, Chen H, Zhang W, Xing C, Qu Z, Yu J, Zhuang C. Structure-based molecular hybridization design of Keap1-Nrf2 inhibitors as novel protective agents of acute lung injury. Eur J Med Chem. 2021 Oct 15;222:113599. doi: 10.1016/j.ejmech.2021.113599. Epub 2021 Jun 5. PMID: 34119834.
5: Sun Y, Huang J, Chen Y, Shang H, Zhang W, Yu J, He L, Xing C, Zhuang C. Direct inhibition of Keap1-Nrf2 Protein-Protein interaction as a potential therapeutic strategy for Alzheimer's disease. Bioorg Chem. 2020 Oct;103:104172. doi: 10.1016/j.bioorg.2020.104172. Epub 2020 Aug 27. PMID: 32890991.
